Dr. Stein is also an active member of several professional and scientific societies and academic committees. A pre-clinical pharmaceutical company, Developing unique, creative and breakthrough immuno-therapies for oncology and autoimmune diseases. Dr. Fiel currently serves on the Advisory Board and Speaker’s Bureau with Pfizer, GlaxoSmithKline, Gilead and Novartis. McCaskill, (9-2, 3KO) was the underdog coming into the DAZN televised bout. We provide them with access to network, executive talent, strategic, operational, and business development resources. Prior to Merck, Dr. Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital. Biond Biologics appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene and a member of Israel Biotech Fund Venture Advisory Team, to its Board of Directors. https://www.linkedin.com/in/robert-glassman-36917b2. Dr. Ingber’s clinical interests include the treatment of urinary and pelvic disorders. He also serves on the boards of the privately held ZappRx and Braeburn. A Phase II Clinical Stage Biotech company developing innovative therapeutics for hematological malignancies and disorders. https://www.linkedin.com/profile/view?id=AAkAAAGJkA4BRMlxJkcLjBd-VRXkUp5vAJV05Y4&authType=NAME_SEARCH&authToken=CjDc&locale=en_US&trk=tyah&trkInfo=clickedVertical%3Amynetwork%2CclickedEntityId%3A25792526%2CauthType%3ANAME_SEARCH%2Cidx%3A1-1-1%2CtarId%3A1448285734635%2Ctas%3Arobert%20spiegel. https://www.linkedin.com/in/yuval-cabilly-4a105b50. Chief Medical Officer, Nevakar, Inc. Dr. Somberg is a pharmaceutical executive with senior leadership experience in global pharma and contract research organizations. In December 2018, PharmaCann entered into an agreement to be acquired by MedMen in a deal valued at $682 million. Former Chief Medical Officer of Schering-Plough and Senior Vice President of the Schering-Plough Research Institute, where he was involved in the filing of over 30 new drug applications. Subscribe to: Posts (Atom) Popular Posts. Gilla joined the Bill and Melinda Gates Foundation (BMGF), first as a member of the Global Health Program Scientific Advisory Committee and subsequently progressing to the position of Director of the TB program for five years. Parking (payable) available at the building.Entrance from HaMada St.Additional parking (payable via app) available ata parking lot on Pekeris St. next to the building. Data is a real-time snapshot *Data is delayed at least 15 minutes. Dr. Gordon received his undergraduate education at the State University of Stony Brook and his M.D and Ph.D. from The Johns Hopkins University School of Medicine. Co-Founder and Managing Partner of Israel Biotech Fund. President of Research & Development, Tessa Therapeutics. is A C-Suite Executive with extensive early and late stage clinical drug development experience leading to the approval of over 10 novel therapies across a broad range of therapeutic areas. Mr. Maisano is an experienced technologist passionate about creating software solutions that improve healthcare. compare medical prices. She serves on the board of Homology Therapeutics. CTO, CareDox. Dr. Barer currently serves on the board of several Biotech companies including TEVA. He previously served as VP of Engineering at Andera and oFlows, and held lead engineering positions with Bank of NY and UnitedHealth Group. Prior to that, he was the President of R&D at Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN). Dr. Cedarbaum then joined Regeneron, where he led the establishment of the clinical development function and served as Program Director and later Vice President of Clinical Affairs. This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities. Mr. Brudnick joined Bioverativ at its spin-off from Biogen where, over the course of nearly 15 years, he initiated, led and completed transactions that now include many of the company’s marketed products and late-stage pipeline programs, including Tecfidera, Spinraza, its biosimilars joint venture with Samsung and its late stage Alzheimer’s programs partnered with Eisai.